X4 Pharmaceuticals (NASDAQ:XFOR) Bolsa

X4 PHARMACEUTICALS INC

X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

SLXN

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

Elon Musk&#8216;s Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is facing safety concerns as it expands its autonomous ride-hailing service in Austin, Texas, spurring doubts if the robotaxi service is scalable.
What Happened: Joe Tegtmeyer, a Tesla owner, had a close call when his autonomous vehicle tried to cross a railroad illegally. Despite the incident, Tegtmeyer supports the idea of more Tesla vehicles on the road to decrease wait times, <a href="https://fortune.com/2025/07/20/elon-musk-tesla-robotaxi-service-austin-scaling-earnings-car-sales/">reported </a>Fortune. 
Check out the current price of&nbsp;<a href="https://benzinga.com/quote/TSLA" target="_blank" rel="noreferrer noopener">TSLA stock here</a>.
Elias Martinez, an early Full Self-Driving beta tester, voiced concerns about the software&#8217;s readiness. He contends that the technology &#8220;nowhere near robust&#8221; to accommodate the 10,000 cars Musk suggested were theoretically feasible. 
Martinez, who also runs the FSD Community Tracker, a platform for data collection and analysis of Tesla&#8217;s self-driving technology, stated that the more cars added, the higher the risk of a collision.&nbsp;He asserted that for any robotaxi service, including Tesla's, to scale safely, it must operate with near-perfect reliability.
He noted that even with substantial improvements over the past four years, the software continues to display serious problems, including running red lights and driving on the wrong side of the road.
He believes Tesla prioritized meeting Musk's June launch deadline over refining the technology, as falling EV demand and the Cybertruck's flop left the CEO needing to reassure investors.
"This feels like a distraction from the declining sales numbers," Martinez stated, adding "Elon is gambling."
See Also: <a href="https://benzinga.com/crypto/cryptocurrency/25/07/46500411/dogecoin-surges-14-in-a-week-is-doge-the-next-treasury-asset-boom" target="_blank" rel="noreferrer noopener">Dogecoin Surges 14% In A Week: Is DOGE The Next Treasury Asset Boom? &#8211; Benzinga</a>
Why It Matters: Despite the concerns, Musk announced that Tesla&#8217;s Full Self-Driving system would see a &#8220;step change improvement&#8221; as the company <a href="https://www.benzinga.com/markets/tech/25/07/46511765/elon-musk-says-teslas-self-driving-tech-is-about-to-get-major-boost-from-austin-robotaxi-upgrades-step-change-improvement">integrates </a>Robotaxi upgrades into its production models.
Furthermore, Gary Black of Future Fund LLC had pointed out that Tesla holds a <a href="https://www.benzinga.com/markets/tech/25/06/46133153/tesla-robotaxi-has-a-major-advantage-over-rivals-waymo-and-zoox-says-gary-black-could-be-very-significant">significant advantage </a>over Robotaxi rivals such as Alphabet Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Waymo and Amazon.com Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Zoox. He emphasized that every Tesla robotaxi produced is ready for deployment right out of the factory. 
This development was expected to significantly enhance Tesla&#8217;s self-driving technology, but the recent safety concerns raise questions about the readiness of the technology for such a major upgrade.
Tesla has strong metrics on Momentum, Quality and Growth, but offers poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">&nbsp;Benzinga Edge Stock Rankings</a>&nbsp;today!
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="789" height="124" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21033230/image-263.png" alt="" class="wp-image-993118" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21033230/image-263.png 789w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21033230/image-263-300x47.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21033230/image-263-768x121.png 768w" sizes="(max-width: 789px) 100vw, 789px" /></figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/management/25/07/46510590/elon-musk-returns-to-intense-work-schedule-back-to-working-7-days-a-week-and-sleeping-in-the-office">Elon Musk Returns To Intense Work Schedule: &#8216;Back To Working 7 Days a Week and Sleeping in the Office</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

News

AMZN

GOOG

GOOGL

Elon Musk Is 'Gambling' With Robotaxi, Says Expert Casting Doubt On Its Scalability And Tech Prowess—'Distraction From The Declining Sales'

Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) plans to start construction on <a target="_blank" href="https://www.benzinga.com/topic/ai-chips" rel="noreferrer noopener">four new fabs</a> later this year, targeting mass production of 2-nanometer chips by late 2028, according to Central Taiwan Science Park Bureau Director-General Hsu Maw-shin.
The new facilities, designated Fab 25, will house four 1.4-nanometer wafer production lines. The contract chipmaker aims to complete risk assessments by 2027 and ramp up to a monthly output of 50,000 wafers, the Taipei Times <a target="_blank" href="https://www.taipeitimes.com/News/front/archives/2025/07/20/2003840583" rel="noreferrer noopener">reported</a> on Sunday.
Taiwan Semiconductor has already leased the land for the new fabs, with the Central Taiwan Science Park transferring the site last month. The park&#8217;s second-phase expansion will begin with soil and water conservation infrastructure, including detention ponds.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46499511/taiwan-semiconductor-cfo-warns-of-margin-pressure-prudent-42-billion-capex-plan" rel="noreferrer noopener">Taiwan Semiconductor CFO Warns Of Margin Pressure, Prudent $42 Billion CapEx Plan</a>
Hsu projected that the park&#8217;s annual turnover will exceed 1.2 trillion New Taiwan dollars ($40.81 billion), setting a new record.
During Taiwan Semiconductor&#8217;s second-quarter earnings call, Chairman C.C. Wei disclosed that the company will allocate about 30% of its 2-nanometer and more advanced chip capacity to Arizona after completing its $165 billion U.S. investment. That investment includes six wafer fabs, two advanced packaging facilities, and a major R&amp;D center.
Wei also said Taiwan Semiconductor plans to build 11 wafer fabs and four advanced packaging facilities globally over the next few years. The company is preparing additional 2-nanometer fabs in Hsinchu and Kaohsiung to meet growing customer demand.
Taiwan Semiconductor closed with a market value above $1 trillion in Taipei for the first time last week, driven by a sharp rise in sales forecasts fueled by soaring demand for artificial intelligence chips.
The chipmaker&#8217;s shares surged to a record high on Friday, marking a nearly 50% gain since April and making it the first Asian stock to top the $1 trillion mark since PetroChina briefly did so in 2007, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-07-21/tsmc-joins-trillion-dollar-club-on-optimism-over-ai-demand?sref=TBDibEcD" rel="noreferrer noopener">reported</a> on Monday. The chipmaker is a key Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) supplier.
The company raised its full-year revenue growth outlook to around 30%, signaling strong positioning amid intensifying competition for AI chip production.
Goldman Sachs analysts, including Bruce Lu, observed that demand for Taiwan Semiconductor&#8217;s advanced nodes continues to grow steadily. They anticipate the company will introduce more significant price increases in 2026 as AI-driven orders remain strong.
Price Action:&nbsp;TSM stock is trading higher by 0.37% to $241.29 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46501869/meta-raids-apples-ai-lab-with-big-paychecks-zuckerberg-bets-to-win-the-ai-race" target="_blank" rel="noreferrer noopener">Meta Raids Apple&#8217;s AI Lab With Big Paychecks—Zuckerberg Bets To Win The AI Race</a></li>
</ul>
Photo by Jack Hong via Shutterstock

Tech

Media

AAPL

NVDA

Taiwan Semiconductor Plans Four New Fabs As AI Gold Rush Continues

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Underperform and lowers the price target from $214 to $210.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Underperform on Marsh & McLennan Cos, Lowers Price Target to $210

Jefferies analyst John Hecht initiates coverage on Jefferson Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCAP#NASDAQ">JCAP</a>) with a Buy rating and announces Price Target of $29.

Initiation

JCAP

Jefferies Initiates Coverage On Jefferson Capital with Buy Rating, Announces Price Target of $29

Parsons Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>), a leader in technology-driven solutions, is proud to announce the development of BlueFly&#x2122;, an innovative search and rescue sensor that enhances the capabilities of emergency response teams. Designed with state-of-the-art technology and affordability in mind, BlueFly&#x2122;&nbsp;aims to revolutionize how agencies conduct search and rescue missions in challenging and remote environments.
Developed by QRC&#xAE;, a Parsons Company, the BlueFly&#x2122;&nbsp;platform leverages the latest advancements in Bluetooth low-energy detection to provide real-time situational awareness support for drone operator first responders. This comprehensive solution accelerates search operations and dramatically improves the probability of survival and outcomes.

Parsons Unveils BlueFly Search Sensor to Boost Drone-Assisted Rescue Missions in Remote Areas

Iron ore prices have rebounded above $100 for the first time since February. Renewed optimism about China's economic resilience and the announcement of construction of the world's largest hydropower dam drove momentum of the futures market in Singapore.
Yet, some analysts believe the rally is unsustainable given the market dynamics and healthy <a target="_blank" href="https://www.benzinga.com/topic/iron-ore" rel="noreferrer noopener">capacity increases from key producers</a>.
In a note cited <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-07-16/iron-ore-tops-100-for-first-time-since-may-on-china-sentiment" rel="noreferrer noopener">by</a> Bloomberg, Citi strategists, including Shreyas Madabushi, warned that "prices are currently above market fundamentals," suggesting a more modest and gradual decline in steel output rather than an aggressive contraction.
Meanwhile, Rio Tinto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) has fast-tracked its timeline for shipments from the massive Simandou iron ore mine in Guinea. The firm expects to ship 0.5 to 1 million tons this November.
While the monumental project could deliver as much as 120 million tons annually, the ramp-up should remain gradual.
RBC analysts forecast output will reach just 12 million tons in 2026 and not top 48 million until 2028.
RIO's rival BHP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) reported a 14% quarter-on-quarter jump in Q4 iron ore production to 70.3 million tons, helping push annual output to a record 290 million tons.
While oversupply looms, official Chinese economic data indicate strong demand, further supported by Premier Li Quiang's Monday announcement.
Quiang broke news on construction of the world's largest hydropower dam on the Yarlung Tsangpo River. The dam, which is expected to exceed the Three Gorges Dam by at least a factor of three, is expected to drive significant demand for construction-grade steel.
Per China Briefing's <a target="_blank" href="https://www.china-briefing.com/news/chinas-economy-in-h1-2025-gdp-trade-and-fdi-highlights/" rel="noreferrer noopener">report</a>, GDP rose 5.3% year-on-year in the first half of 2025, with industrial output up 6.4%, services growing 5.5%, and retail sales up 5.0%. Fixed asset investment rose 2.8%, led by manufacturing, and disposable income grew 5.4% in real terms. National Bureau of Statistics Deputy Head Sheng Laiyun called the results a "hard-won achievement" amid global volatility.
Former Australian Ambassador to China Geoff Raby noted that Prime Minister Anthony Albanese's latest visit to China provides an opportunity.
"Although China's growth in demand for Australian iron ore is tapering off, the absolute volume we sell is so large that even a small uptick in demand will lead to tremendous increases in volume," Raby <a target="_blank" href="https://www.youtube.com/watch?v=VuBsZheeGB8" rel="noreferrer noopener">told</a> ABC. "It's a two-way relationship," he added, arguing that China's pivot to green steel is not a threat, but a future opportunity for Australian producers.
"We have massive potential in terms of renewable energy. Ross Garnaut has written about this on numerous occasions in books, and he talks about Australia being the energy superpower of the future because of this very reason."
Raby also clarified that Australia must balance its engagement with China against global pressures, especially from the U.S.
"The Prime Minister has stuck to our strong commitment to free trade, and has not gone down the path of retaliatory tariffs. So, I think that puts us in a very strong position," he said.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/node/46438534" target="_blank" rel="noreferrer noopener">Three Factors Keeping Gold's Momentum In 2025: Report</a></li>
</ul>
Photo by saweang.w via Shutterstock

Asia

Commodities

Politics

Global

Markets

China-Led Rally Sends Iron Ore Over $100 Despite Looming Oversupply

TD Cowen analyst Bill Katz upgrades Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) from Hold to Buy and raises the price target from $17.5 to $25.

Upgrades

TD Cowen Upgrades Invesco to Buy, Raises Price Target to $25

Trading Halt: Halted at 6:20:03 a.m. ET - Trading Halt: Halt News Pending

Earnings

Domino's Pizza Reported 5.6% Global Retail Sales Increase Backed By 148 International And 30 US Store Openings

Domino's Pizza's Same Store Sales Rise 3.4% In US And 2.4% Internationally, Ex-FX

Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Outperform and raises the price target from $69 to $73.

Keefe, Bruyette & Woods Maintains Outperform on Comerica, Raises Price Target to $73

GigaMedia Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIGM#NASDAQ">GIGM</a>) today announced that the Company has entered into and executed an agreement to purchase a US$1,500,000 principal amount of convertible promissory note (the "Note") issued by Aeolus Robotics Corporation ("Aeolus"), a global company primarily engaged in designing, manufacturing, processing and sales of intellectual robotics.
&nbsp;
The Note, bearing interest at a rate of 4.5% per annum, shall be due in 36 months, and all or a portion of the principal amount under the Note may be convertible at GigaMedia's option upon maturity, upon prepayment, or when certain events occur, into ordinary shares of Aeolus at a price of US$0.02 per share.
&nbsp;
The purchase and sale of the Note exhibits GigaMedia and Aeolus's mutual commitment to a longer-term strategic relationship. GigaMedia continually reviews its investment alternatives and may enter into additional transactions of Aeolus's securities in accordance with applicable laws.

GIGM

GigaMedia Invests $1.5M in Aeolus Robotics Via Convertible Note With 4.5% Interest Over 3 Years

Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) reported quarterly earnings of $3.81 per share which missed the analyst consensus estimate of $3.93 by 3.15 percent. This is a 5.46 percent decrease over earnings of $4.03 per share from the same period last year. The company reported quarterly sales of $1.15 billion which beat the analyst consensus estimate of $1.14 billion by 0.13 percent. This is a 4.28 percent increase over sales of $1.10 billion the same period last year.

Earnings Beats

Earnings Misses

Domino's Pizza Q2 EPS $3.81 Misses $3.93 Estimate, Sales $1.15B Beat $1.14B Estimate

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Outperform and raises the price target from $102 to $108.

SCHW

Keefe, Bruyette & Woods Maintains Outperform on Charles Schwab, Raises Price Target to $108

SQNS

Sequans Adds 1,264 Bitcoin For $150M, Boosts Treasury Holdings To 2,317 BTC

Keefe, Bruyette &amp; Woods analyst Chris O'Cull maintains Chemung Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHMG#NASDAQ">CHMG</a>) with a Market Perform and raises the price target from $55 to $59.

CHMG

Keefe, Bruyette & Woods Maintains Market Perform on Chemung Financial, Raises Price Target to $59

GLDG

GoldMining Taps Copper Surge With Over 1.7 Billion Pounds In Resources Across Americas

The Ether Machine, Inc. ("the Company" or "The Ether Machine"), a newly formed entity enabling public market investors to access Ethereum yield, announced its public launch today through a definitive business combination agreement between The Ether Reserve, LLC and Dynamix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNX#NASDAQ">DYNX</a>). Upon the closing of the business combination, the combined entity will trade on NASDAQ under the ticker symbol "ETHM".
The Ether Machine is building the largest public vehicle for institutional-grade exposure to&nbsp;Ethereum, offering secure, transparent, and compliant access to ETH-denominated yield. As a strategic Ether generation company, it aims to deliver long-term, risk-adjusted returns through staking, restaking, and decentralized finance strategies.

IPOs

DYNX

The Ether Machine to Go Public via Merger With Dynamix, Will Trade on NASDAQ as 'ETHM'

Priscilla Chan says advanced GPU clusters aren't just a lure for Silicon Valley, biologists want them, too.
What Happened: Speaking on Ashlee Vance's Core Memory <a href="https://www.youtube.com/watch?v=F1-MFboIASg">podcast</a>, the Chan Zuckerberg Initiative (CZI) co‑founder said the nonprofit now fields roughly 1,000 high‑end graphics chips and is buying more so researchers can do the work they want to do, even if CZI cannot match Big Tech salaries.
Her remarks land as husband Mark Zuckerberg's new Superintelligence Labs woos AI engineers with eight‑figure packages and a pledge to control 1.3 million GPUs by year‑end.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Priscilla Chan&#039;s Multi-Billion Dollar Quest to End Disease" width="500" height="281" src="https://www.youtube.com/embed/F1-MFboIASg?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
"The other thing researchers really care about is access to GPUs," Chan said. "You're not going to make the most of someone if you don't actually have the GPUs for them to work from." CZI's cluster sits at about 1,000 GPUs, with plans to keep growing, she added.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46511927/dave-portnoys-10-million-elon-musk-bet-pays-off-as-tesla-soars-12-in-two-weeks-thats-a-million-bucks">Dave Portnoy&#8217;s $10 Million Elon Musk Bet Pays Off As Tesla Soars 12% In Two Weeks: &#8216;That&#8217;s A Million Bucks&#8217;</a>
Chan tells candidates, "Come work with us because we're going to have the computing power to support the research that you want to do." Pay, she concedes, is "obviously important," yet "we cannot compete with tech companies on this."
The organization has tightened its focus to a "science‑first philanthropy," devoting its biggest bets to biomedical discovery.
Why It Matters: Meta's CEO has a different magnet and that&#8217;s money. Zuckerberg <a href="https://www.threads.com/@theinformation/post/DMGueMrvzTn?xmt=AQF01JbYaFpSpZjtgyA4hVgBJbrdte7zTgFAD6II1raMTQ">told</a> The Information recently that recruits want "the fewest number of people reporting to me and the most GPUs." Meta will spend up to <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43196266/whats-going-on-with-meta-shares-friday-2">$65 billion this year</a> and expects "over 1.3 million graphics processors" online by December.
Meta last week <a href="https://www.benzinga.com/markets/tech/25/07/46434602/mark-zuckerbergs-meta-poaches-top-openai-researchers-jason-wei-and-hyung-won-chung-for-its-superintelligence-lab-report">hired two top researchers</a> from OpenAI for its ambitious new superintelligence lab. This recruitment comes amid a wave of aggressive AI hiring by the company, which has reportedly offered compensation packages of up to $300 million over four years to lure talent from rivals.
That said, analysts warn that Meta's spree will <a href="https://www.benzinga.com/25/01/43214849/mark-zuckerbergs-65-billion-bet-benefits-nvidia-and-other-ai-players-top-analyst-warns-the-run-will-end-in-a-spectacular-bubble-burst">inflate GPU prices</a> and could crowd out nonprofits unless vendors offer discounted cycles.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46513294/nvidia-ceo-jensen-huang-says-hed-ditch-software-for-physical-sciences-if-he-were-20-today">Nvidia CEO Jensen Huang Says He&#8217;d Ditch Software For Physical Sciences If He Were 20 Today</a></li>
</ul>
Image Via Shutterstock

Mark Zuckerberg's Wife Priscilla Chan Reveals Her Secret Weapon To Lure Top Talent To CZI — And It's Not Eight-Figure Salaries Like Her Husband Offers At Meta

Wag! Initiates Chapter 11 Proceeding In Delaware Court As Part Of Recapitalization With Primary Lender Retriever

Press Releases

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Reverse Stock Split

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host  Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Health Care

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

General

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Comments

X4 Pharmaceuticals

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL